Opinion|Videos|October 7, 2024
Inclusion of Chemotherapy and Impact on Outcomes From the ARASENS Trial
Author(s)Fred Saad, CQ, MD, FRCS, FCAHS
Key Takeaways
- Chemotherapy, particularly docetaxel, significantly influences the adverse event profile, with common side effects including neutropenia, fatigue, and diarrhea.
- The ARASENS trial findings align with previous studies, confirming the consistency of observed adverse effects with clinical practice.
Fred Saad, CQ, MD, FRCS, FCAHS, discusses how the inclusion of chemotherapy, particularly docetaxel, in combination therapies for metastatic prostate cancer alters the adverse event profile, noting that while the ARASENS trial found adverse effects to be largely consistent with previous docetaxel studies, they consider whether this aligns with observations in clinical practice.
Advertisement
Video Content above is prompted by the following:
- How does inclusion of chemotherapy affect the adverse event profile? In the ARASENS trial (NCT02799602), authors concluded that many of the adverse effects were consistent with those observed in previous studies with docetaxel. Is this consistent with what you see in clinical practice?
Advertisement
Related to this article
Abraham Morgentaler, MD, reviews evidence showing no association between testosterone therapy and prostate cancer risk and explains the saturation model of androgen action.
Based on these results, the trial protocol has been amended to move enrollment earlier in the course of disease progression.
An analysis of NRG/RTOG 0815 found Decipher predicted distant metastasis risk and identified patients with greater benefit from short-term ADT.
Exploratory analyses suggest persistent immune remodeling after aglatimagene plus radiation in localized prostate cancer.
Brian Mazzarella, MD, discusses the landscape for intermediate-risk prostate cancer and early VAPOR 2 findings on water vapor ablation.
The phase 3 BiPASS trial is evaluating the use of 68Ga-PSMA-PET in combination with MRI for pre-biopsy prostate cancer detection.
In RTOG 3506, adding enzalutamide to standard ADT and salvage radiotherapy was associated with 2-year PFS benefit.
In the phase 3 PACE-A trial, SBRT and prostatectomy showed similar 8-year disease control in localized prostate cancer, with lower rates of urinary incontinence after SBRT.
Advertisement
Advertisement
Trending on Urology Times
1
Avoiding False Positives on Prostate Cancer PSMA PET Scans
2
Decipher may help identify ADT benefit in intermediate-risk prostate cancer
3
2026 AUA/SUO NMIBC guideline: Key updates for clinical practice
4
AUA South Central Section Meeting: Mark D. Tyson, II, MD, MPH, recaps data in NMIBC
5